Abstract:Responding to the tumor microenvironment, functional polymers can serve as preeminent drug carriers for targeted cancer therapy. Stimuli-responsive polymeric drug carriers are reported with diverse anti-tumor effects for various polymer structures. Thus, three pH/redox dual-responsive amphiphilic zwitterionic polymer 'isomers' with different locations of pH/redox responsive units were prepared to understand the relationship between polymer structure and anti-tumor effect. Containing poly(epsilon-caprolactone) (PCL), poly(N,N-diethylaminoethyl methacrylate) (PDEA) and poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC), polymers PCL-ss-P(DEA-r-MPC) (SDRM), PCL-ss-PDEA-b-PMPC (SDBM) and PCL-PDEA-ss-PMPC (DSM) with a precisely controlled structure were constructed and confirmed through NMR, FITR and EA. The formed micellar drug carriers were characterized by their morphology, loading capacity, acid/redox sensitivity, drug release, in vitro cytotoxicity and in vivo antitumor effects. Micelles with uniform spherical morphologies can effectively encapsulate anti-tumor drugs such as DOX. Among these micelles, DSM@DOX displays the most excellent drug encapsulation capacity (13.4%) with neutral surface charge (-1.02 mV) and good stability, and is different from SDRM@DOX with positive charge (+11.1 mV) and SDBM@DOX with poor stability. All micelles respond to acid and reducing environments and present fast drug release at mildly acidic pH and high concentrations of GSH, exhibiting low burst release under the physiological conditions of plasma. There is no significant difference between these micelles in tumor cell cytotoxicity against MCF-7 and 4T1 cells. Internalization of SDRM@DOX and DSM@DOX by the tumor cells is stronger than that of SDBM@DOX. Notably, DSM@DOX has longer blood circulation and more effective accumulation at the tumor site than the other two micelles. As a result, DSM@DOX shows enhanced antitumor efficacy in 4T1 tumor-bearing mice with reduced side toxicities. Overall, structures of the above polymers significantly influence the in vivo antitumor effects of the drug carriers through blood circulation and cellular uptake.

Development of Stimuli-Responsive Intelligent Polymer Micelles for the Delivery of Doxorubicin

Supramolecular polymeric prodrug micelles for efficient anticancer drug delivery

The Development of Stimuli-Responsive Polymeric Micelles for Effective Delivery of Chemotherapeutic Agents

Dual-Triggered Peptide-Based Polymeric Micelles Enhance Doxorubicin Delivery for Targeted Cancer Therapy

Ph-Sensitive Polymeric Nanoparticles for Tumor-Targeting Doxorubicin Delivery: Concept and Recent Advances

Crgd-Functionalized Polymer Micelles for Targeted Doxorubicin Delivery

Biodegradable Redox-Sensitive Star Polymer Nanomicelles for Enhancing Doxorubicin Delivery

Reduction/temperature/pH Multi-Stimuli Responsive Core Cross-Linked Polypeptide Hybrid Micelles for Triggered and Intracellular Drug Release.

Crgd Targeted and Charge Conversion-Controlled Release Micelles for Doxorubicin Delivery

Integrin-targeted pH-responsive micelles for enhanced efficiency of anticancer treatment in vitro and in vivo.

Cell Membrane-Inspired Polymeric Micelles As Carriers for Drug Delivery

Ph-Responsive Hyperbranched Polypeptides Based on Schiff Bases As Drug Carriers for Reducing Toxicity of Chemotherapy

Tumor Microenvironment-Responsive Micelles for Pinpointed Intracellular Release of Doxorubicin and Enhanced Anti-Cancer Efficiency.

Targeted delivery by pH-responsive mPEG-S-PBLG micelles significantly enhances the anti-tumor efficacy of doxorubicin with reduced cardiotoxicity

Beta-Cyclodextrin-Centered Star-Shaped Amphiphilic Polymers for Doxorubicin Delivery

pH/redox dual-responsive amphiphilic zwitterionic polymers with a precisely controlled structure as anti-cancer drug carriers.

Ph-Responsive Polymeric Micelles Based on Poly(2-Ethyl-2-oxazoline)-poly(d,l-lactide) for Tumor-Targeting and Controlled Delivery of Doxorubicin and P-glycoprotein Inhibitor

Doxorubicin Loaded Ph-Responsive Micelles Capable of Rapid Intracellular Drug Release for Potential Tumor Therapy.

Bicomponent Polymeric Micelles for Ph-Controlled Delivery of Doxorubicin

pH-sensitive doxorubicin-conjugated prodrug micelles with charge-conversion for cancer therapy

Development and Evaluation of pH‐Responsive Microbeads Incorporated with Nickel Zinc Ferrite Nanoparticles for Controlled Release of Doxorubicin